Jiangbo Pharmaceuticals (ehem. GNPH) - A0RNJB/JGBO
Du spielst hier den Alleinunterhalter und bist euphorisch.
Kannst Du mir das erklären?
Seit heute traden wir am NASDAQ nur zur Info.
Und ob ich alleinunterhalter bin das lass mal meine Sorge sein.
Optionen
| Boardmail an "datschi" |
Wertpapier: JIANGBO PHARMACEUTICALS |
Laiyang, China, 10. Juni 2010 / PRNewswire / - Jiangbo Pharmaceuticals, Inc. / quotes/comstock/15 *! Jgbo / quotes / nls / jgbo (JGBO 8.23, -0,17, -2,02%) (das "Unternehmen "oder" Jiangbo "), gab heute bekannt, dass das Unternehmen die Zustimmung der chinesischen State Food and Drug Administration (" SFDA ") zu produzieren Felodipin retardierte (" SR ") Tabletten erhalten.
Felodipin SR ist ein anerkanntes generisches Medikament zur Behandlung von Bluthochdruck und ist in China's Basic Medical Insurance Katalog für medizinische Versorgung aufgeführt. A 2009 Studie von Forschern in den USA und in China durchgeführt, die von der Tulane University führte, dass schätzungsweise etwa 153 Millionen Menschen in China Hypertonie und weniger als 5% der Hypertoniker Behandlung erhalten hatten. Zwar gibt es derzeit einige andere Pharmafirmen verkauft Felodipin SR Tabletten, glaubt das Unternehmen, dass der Markt die Möglichkeit sehr groß ist und Pläne zur Nutzung seiner starken nationalen Verteilung Beziehungen effektiv durchdringen den Markt eindringen und zu teilen. Viele der aktuellen Händler Jiangbo Interesse an einer Zusammenarbeit mit der Gesellschaft zu Felodipin SR Tabletten und Jiangbo verteilen geäußert haben auch erwartet, dass Gespräche mit zahlreichen neuen Distributoren initiieren zu helfen, die Vermarktung dieses Medikaments in Einzelhandels-und Krankenhaus Vertriebskanäle.
Jiangbo glaubt, dass es die notwendigen Produktionsanlagen und Kapazitäten zur Felodipin SR-Tabletten zu produzieren hat. Das Unternehmen rechnet mit der Vorserie Anforderungen vollständig und erhalten Endverteilung Genehmigung von Shandong Food and Drug Administration im Juli 2010. Das Unternehmen plant den kommerziellen Vertrieb unmittelbar nach dem Erhalt einer solchen Genehmigung einzuleiten. Das Management erwartet, dass die Droge eine sinnvolle Beitrag zum Umsatz und Ergebnis ab dem Geschäftsjahr 2011 und die Schätzungen Umsatzpotenzial für das Medikament werden, die zwischen $ 8.000.000 und 12.000.000 $ in den ersten zwölf Monaten nach der Markteinführung mit einem prognostizierten Bruttomarge von mindestens 70% .
"Wir freuen uns sehr, diese wichtige Genehmigung Felodipin SR Tabletten, die wir glauben, wird eine wichtige Umsatz-und Gewinnwachstum Treiber für uns in den nächsten Jahren produzieren zu erhalten", sagte Herr Cao WUBO, Chairman und CEO von Jiangbo Pharmaceuticals. "Wir sind bereits der Vorbereitung der kommerziellen Produktion und Markteinführung von Felodipin SR Tabletten und planen sorgfältig auswählen Händler zu unserem kommerziellen Chancen für dieses neue Medikament zu maximieren. Wir glauben, dass die Zugabe von Felodipin SR Tabletten bereichern unser Produktportfolio und unsere Wettbewerbsposition zu stärken Marktposition , während die Bereitstellung kostengünstiger neues Medikament zur Deckung der wachsenden Nachfrage Patienten. "
Über Jiangbo Pharmaceuticals, Inc.
Date : 06/10/2010 @ 9:00AM
Source : PR Newswire
Stock : Jiangbo Pharmaceuticals (MM) (JGBO)
Quote : 8.47 0.43 (5.35%) @ 11:51AM
Jiangbo Pharmaceuticals Receives Approval for Felodipine Sustained Release Tablets
Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or "Jiangbo"), today announced that the Company received approval from the Chinese State Food and Drug Administration ("SFDA") to start producing Felodipine sustained release ("SR") tablets.
Felodipine SR is a well recognized generic drug to treat hypertension and is listed in China's Basic Medical Insurance Catalog for medical coverage. A 2009 study conducted by researchers in the U.S. and China, led by Tulane University, estimated that approximately 153 million people had hypertension in China and less than 5% of the hypertensives received treatment. While there are currently several other pharmaceutical companies selling Felodipine SR tablets, the Company believes that the market opportunity is very large and plans to leverage its strong national distribution relationships to effectively penetrate the market and gain share. Many of Jiangbo's current distributors have expressed interest in cooperating with the Company to distribute Felodipine SR tablets and Jiangbo also expects to initiate discussions with numerous new distributors to help expand the marketing of this drug across retail and hospital sales channels.
Jiangbo believes that it has the necessary manufacturing equipment and capacity to produce Felodipine SR tablets. The Company expects to complete the pilot production requirements and receive final distribution approval from Shandong Food and Drug Administration in July 2010. The Company plans to initiate commercial distribution immediately following the receipt of such approval. Management anticipates the drug to be a meaningful contributor to its revenue and profit starting in fiscal 2011 and estimates revenue potential for this drug to be between $8 million and $12 million in the first twelve months of launch with a projected gross margin of at least 70%.
"We are very excited to receive this important approval to produce Felodipine SR tablets, which we believe will be a key revenue and profit growth driver for us in the next few years," said Mr. Cao Wubo, Chairman and CEO of Jiangbo Pharmaceuticals. "We are already preparing for the commercial production and launch of Felodipine SR tablets and plan to carefully select distributors to maximize our commercial opportunity for this new drug. We believe the addition of Felodipine SR tablets will enrich our product portfolio and strengthen our competitive market position, while providing more cost effective new medicine to meet growing patient demand."
About Jiangbo Pharmaceuticals, Inc.
Jiangbo is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to successfully launch and commercialize Felodipine SR tablets, obtain raw materials needed for product manufacturing, anticipated sales volume growth of the drug, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-903-9378 x2
Email: elsasung@jiangbo.com
Web: http://www.jiangbopharma.com
CCG Investor Relations
Ms. Lei Huang, Account Manager
Phone: +1-646-833-3417
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
SOURCE Jiangbo Pharmaceuticals, Inc.
http://ih.advfn.com/p.php?pid=nmona&article=43178136
http://finance.yahoo.com/marketupdate/inplay
Nach dem Uplisting - auf das alle sehnlichst gewartet hatten - war doch mit etwas mehr Bewegung zu rechnen, oder?
Im wo wird schon vermutet, dass hier etwas "oberfaul" sei.
Es wäre für mich nicht das erste Mal, wenn ich hier zur falschen Zeit investiert hätte.
Wann kommen die nächsten Zahlen?
Für Infos über Jiangbo wäre ich sehr dankbar.
Entweder hat Pope seine warrents schon verkauft,oder jiangbo selbst verkauft für den mergerfond.
Allerdings müsste jiangbo das melde,normalerweise.....
Die chinesischen Aktien an der Nasdaq kamen durch Ungereimtheiten in ein schlechtes Licht.
Vielleicht werden alle über einen Kamm gezogen,zum Nachteil von jangbo.
Viel Glück den Investierten
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48612194
| _bbb_  | Share | Monday, April 05, 2010 4:25:18 PM | |
| Re: None | Post # of 7259 |
JGBO CHARTS
Daily SMA 5 10 20 / LOG OFF
Daily / LOG ON
Weekly / LOG ON
Daily SMA 5 10 20 / LOG OFF
Daily / LOG ON
Weekly / LOG ON
Für donnerstag ist eine telefonkonferenz angesagt.
http://finance.yahoo.com/news/...-prnews-989136052.html?x=0&.v=51
REVENUES 97,444 ist zwar weniger als letzte Jahr,allerdings
durch eine Produktionsabstellung.
NET INCOME 29,850 sogar mehr als letztes Jahr.
Mensch,fast 30 mill USD Gewinn.
und Cash, end of the year $ 108,616,735 ...
Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
prnewswire
*
Share
*
retweet
*
Companies:
o Jiangbo Pharmaceuticals, Inc
*
Topics:
o Earnings
Related Quotes
Symbol Price Change §
JGBO 7.85 0.00§
Chart for Jiangbo Pharmaceuticals, Inc.
{"s" : "jgbo","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Jiangbo Pharmaceuticals, Inc. On Thursday September 30, 2010, 7:00 am
LAIYANG, China, Sept. 30 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq:JGBO - News) ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010. The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission and is available on the Company's website.
Fiscal Year 2010 Corporate Event Highlights
-- On June 8, 2010, Jiangbo's common stock began trading on The NASDAQ
Global Market
-- On June 10, 2010, Jiangbo announced that it had obtained SFDA approval
to produce Felodipine sustained release tablets, which is a well
recognized generic drug to treat hypertension
-- Effective July 1, 2010, Mr. Linxian Jin took over the role of CEO from
the Company's Chairman, Mr. Wubo Cao, who will continue his role as the
Chairman of the Company's Board
Fourth Quarter FY 2010 Highlights:
-- Revenues decreased 5.9% year-over-year to $29.3 million
-- Gross profit was $21.1 million, a 8.2% decrease from the comparable
period in 2009
-- Operating income decreased 17.1% year-over-year to $14.7 million
-- Net income decreased 37.5% to $7.2 million, or $(0.39) per fully
diluted share
-- Non-GAAP adjusted net income was $9.8 million, or $0.65 per fully
diluted share, for the three months ended June 30, 2010, down 19.1%
from non-GAAP adjusted net income of $12.1 million, or $0.81 per fully
diluted share, for the quarter ended June 30, 2009
Fiscal Year 2010 Highlights:
-- Total revenue decreased 17.0% year-over-year to $97.4 million
-- Gross profit decreased 20.3% to $71.3 million, as compared to the
results in fiscal year 2009
-- Operating income decreased 3.1% year-over-year to $48.2 million
-- Net income grew 3.4% to $29.9 million, as compared to the results in
fiscal year 2009
-- Non-GAAP adjusted net income was $30.9 million, or $2.04 per fully
diluted share in fiscal year of 2010, down 13.0% from non-GAAP adjusted
net income of $35.6 million, or $2.46 per fully diluted share in fiscal
year 2009
"Fiscal year 2010 was a transitional year for Jiangbo as we worked to upgrade our traditional Chinese medicine ("TCM") production facility and prepared for the introduction of new drugs. We are very pleased to have our shares begin trading on The NASDAQ Global Market, which is a significant milestone for our company," commented Mr. Jin, Jiangbo's Chief Executive Officer. "We are encouraged by the SFDA approval of our sustained release Felodipine tablets, which we believe will help counterbalance revenue declines of some of our more mature products such as Itopride and Baobaole Chewable tablets. While we have experienced delays in the renovation of our Hongrui facility for traditional Chinese medicine, we now expect to commence production of six of Hongrui's TCM products in October."
Fourth Quarter Results
Total revenue decreased 5.9% year-over-year to $29.3 million from $31.2 million. The Company carried five drugs during the quarter ended June 30, 2010, with Clarithromycin sustained release tablets accounting for 43.0% of total sales, Itopride Hydrochloride granules 24.4%, Baobaole chewable tablets 16.7%, and Radix Isatidis dispersible tablets 15.7% during the quarter. The year- over-year decrease in fiscal fourth quarter 2010 revenues reflects a 30.5% decline in sales of Baobaole chewable tablets, partly offset by sales increases of Clarithromycin sustained release tablets and Radix Isatidis dispersible tablets by 21.9% and 45.1%, respectively.
Gross profit decreased 8.2% to $21.1 million, from $23.0 million in the comparable period of fiscal year 2009. Gross margin decreased to 72.0% from 73.8% in the year ago quarter, mainly reflecting higher raw material costs for TCM herbs due to natural disasters in Southern China during the second half of fiscal year 2010. During the fourth quarter of fiscal year 2010, TCM accounted for about 20% of total cost of sales.
Selling, general and administrative expenses increased 26.8% to $5.3 million from $4.2 million in the same period of fiscal year 2009, primarily due to more marketing and promotional expenditures in the last quarter of fiscal year 2010 and more public company related expenses that were incurred in the same quarter.
Operating income decreased 17.1% to $14.7 million, as compared to $17.7 million in the same period of fiscal year 2009. Operating margin as a percentage of revenue decreased to 50.1% from 56.8% in the same period of fiscal year 2009.
Other expenses, comprised primarily of interest expenses, amortization expenses on convertible debentures, and change in fair value of derivative liabilities, were $3.2 million compared to $1.5 million for the three months ended June 30, 2009. Interest expense increased 140.5% to $4.2 million in the fourth quarter of fiscal year 2010, compared to $1.8 million in the year ago period, as a result of additional penalty interest incurred due to the Company's delinquency in paying interest to its convertible debenture holders and its convertible note holders, and significantly increased amortization expenses related to write off of unamortized debt discount as convertible notes were converted into the Company's common shares.
The provision for income taxes was $4.3 million in the fourth quarter of fiscal year 2010, compared to $4.7 million for the three months ended June 30, 2009.
Net income decreased 37.5% to $7.2 million from $11.5 million in the prior year's comparable period, representing basic earnings per share of $0.62. Diluted earnings per share for the fourth quarter of fiscal year 2010 were $(0.39).
Excluding the impact of a loss from discontinued operations of approximately $43,023, an unrealized loss on investments of $0.1 million, a gain in fair value of derivative liabilities of $1.1 million, and amortization of debt discount and issuance costs related to convertible debentures of $3.5 million, non-GAAP adjusted net income for the fourth quarter of fiscal year 2010 was $9.8 million, or $0.85 per basic share, as compared to $12.1 million, or $1.15 per basic share, in the fourth quarter of fiscal year 2009. Non GAAP adjusted fully diluted earnings per share were $0.65, as compared to $0.81 in the fourth quarter of fiscal year 2009. (For a reconciliation of adjusted non- GAAP net income and basic and diluted earnings per share with their nearest GAAP equivalents, please see the table at the end of this press release.)
Fiscal Year 2010 Results
Total revenue for fiscal year 2010 decreased 17.0% to $97.4 million from $117.4 million in fiscal year 2009. Gross profit decreased 20.3% to $71.3 million, as compared to $89.5 million in the prior year. Gross margin was 73.2%, compared to 76.2% last year, primarily due to reduced per unit sales prices as part of the Company's effort to restructure its distribution and sales system in January 2009 and, to a lesser extent, due to higher TCM herb raw material costs during second half of fiscal year 2010. Operating income decreased 3.1% to $48.2 million from $49.8 million in fiscal year 2009. Operating margin increased to 49.5% from 42.4% in the prior year, mainly reflecting significantly reduced commission to the Company's sales representatives after the distribution restructuring. Net income increased 3.4% to $29.9 million, as compared to $28.9 million in fiscal year 2009. Net margin as percentage of revenue expanded 6.0 percentage points to 30.6% from 24.6% in the comparable period. Fully diluted earnings per share were $1.36, compared to $0.09 in fiscal year 2009.
Excluding the impact of a loss from discontinued operations of $0.2 million, an unrealized gain on investments of $0.2 million, a gain in fair value of derivative liabilities of $14.6 million and amortization of debt discount and issuance costs related to convertible debentures of $15.6 million, non-GAAP adjusted net income for fiscal year 2010 was $30.9 million, or $2.79 per basic share, as compared to $35.6 million, or $3.54 per basic share, in fiscal year 2009. Non-GAAP adjusted diluted earnings per share were $2.04 in fiscal year 2010, as compared to $2.46 in fiscal year 2009.
Financial Condition
As of June 30, 2010, the Company had $108.6 million in cash, as compared to $104.4 million at the end of fiscal year 2009. Working capital was $88.5 million, down from $99.8 million as of June 30, 2009. Shareholders' equity was $134.5 million, as compared to $126.1 million at the end of fiscal year 2009.
The Company generated $20.3 million in cash flow from operating activities in fiscal year 2010. Net cash flow used in investing activities was $16.6 million in fiscal year 2010, which was primarily used to purchase land use rights of approximately $17.0 million, partially offset by proceeds of approximately $0.5 million from the sale of investments.
Due to restrictions on the Company's ability to transfer cash out of the PRC, the Company is delinquent in the payment of interest on its November 2007 Debentures and May 2008 Notes. Management has been in close discussions with holders of the November 2007 Debentures and May 2008 Notes in order to reach a resolution to this issue in the near-term.
Business Outlook and Guidance
Combined sales of the Company's top four products in fiscal year 2010 are expected to decline by 15% to 20% in fiscal year 2011, reflecting intensifying competition and the Chinese government's control over drug pricing under recent health care reform policies.
Incremental sales from the Company's recently approved Felodipine sustained release tablets and from the Company's TCM products to be manufactured at Hongrui are expected to largely offset this decline in 2011.
Management estimates that the portfolio of TCM drugs to be manufactured at Hongrui will generate revenues of $7 million to $15 million during the first year of production, beginning in the second quarter of fiscal year 2011. Felodipine is expected to generate revenues of $8 million to $12 million during the first twelve months after its launch, which took place in the first quarter of fiscal year 2011.
Based on current information, the Company expects that revenues for fiscal year 2011 will be in the range of $94 million and $96 million and net income, excluding the impact from change in fair value of derivative liabilities and expenses related to the Company's convertible debentures, will be in the range of $29 million and $31 million.
"We believe that our strong balance sheet and cash position provides Jiangbo with unique flexibility to acquire innovative new products and pursue strategic acquisitions. Presently we are evaluating select opportunities to enhance our growth prospects, strengthen our market position and vertically integrate our operations. With the transitional year of 2010 behind us, we believe that we are well positioned to create value for shareholders in 2011 and beyond," commented Mr. Jin.
Conference Call
Combined sales of the Company's top four products in fiscal year 2010 are expected to decline by 15% to 20% in fiscal year 2011, reflecting intensifying competition and the Chinese government's control over drug pricing under recent health care reform policies.
Incremental sales from the Company's recently approved Felodipine sustained release tablets and from the Company's TCM products to be manufactured at Hongrui are expected to largely offset this decline in 2011.
Management estimates that the portfolio of TCM drugs to be manufactured at Hongrui will generate revenues of $7 million to $15 million during the first year of production, beginning in the second quarter of fiscal year 2011. Felodipine is expected to generate revenues of $8 million to $12 million during the first twelve months after its launch, which took place in the first quarter of fiscal year 2011.
Based on current information, the Company expects that revenues for fiscal year 2011 will be in the range of $94 million and $96 million and net income, excluding the impact from change in fair value of derivative liabilities and expenses related to the Company's convertible debentures, will be in the range of $29 million and $31 million.
"We believe that our strong balance sheet and cash position provides Jiangbo with unique flexibility to acquire innovative new products and pursue strategic acquisitions. Presently we are evaluating select opportunities to enhance our growth prospects, strengthen our market position and vertically integrate our operations. With the transitional year of 2010 behind us, we believe that we are well positioned to create value for shareholders in 2011 and beyond," commented Mr. Jin.
Hier ein Link zu den letzten Finanzdaten.
http://finance.yahoo.com/q/bs?s=JGBO+Balance+Sheet&annual
Zwar ist der Ausblick für 2011 enttäuschend,allerdings ist und bleibt es spannend.
Mit soviel Cash lässt sich Einiges anfangen.